MENTOR
2019
Membranous Nephropathy Trial of Rituximab
In 130 patients with membranous nephropathy at moderate-to-high risk, rituximab achieved more complete or partial remission at 24 months than cyclosporine.
Result
- Absolute difference
- 40 points
- NNT
- 3
risk difference4095% CI 25-55 · P < 0.001
Absolute difference and NNT are derived from the event rates.
Also reported: Superiority); noninferior at 12mo (60% vs 52%, P=0.004).
- Subtopic
- Membranous nephropathy
- Design
- Open-label RCT
- Relevance
- Important: one of several pillars.
- Cited in
- KDIGO 2021 Glomerular Diseases
- Source
- Fervenza FC, et al. N Engl J Med. 2019;381(1):36-46.doi 10.1056/NEJMoa1814427
Discussion & critique
Established rituximab as a first-line option in KDIGO 2021; deeper and earlier anti-PLA2R decline than with cyclosporine.